Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Efficacy and Safety of Biosimilar Rituximab in Patients With Pemphigus Vulgaris: A Prospective Observational Study Publisher Pubmed



Toosi R1 ; Mahmoudi H1 ; Balighi K1 ; Teimourpour A1, 2 ; Alaeen H1 ; Shaghaghi M3 ; Abedini R1 ; Daneshpazhooh M1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Dermatology, Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins Hospital, Baltimore, MD, United States

Source: Journal of Dermatological Treatment Published:2021


Abstract

Background: The optimal treatment for pemphigus vulgaris (PV) has not been clearly determined yet. Rituximab (RTX) was recently approved for the management of adults with moderate to severe PV. Objectives: This prospective observational study was designed to evaluate the efficacy and safety of biosimilar RTX in PV patients. Methods: The efficacy and safety were evaluated by assessing the pemphigus disease area index (PDAI) score, clinical response and any adverse events (AEs) during at least 12-month follow-up. We evaluated anti-desmoglein (Dsg) 1,3 level at baseline, 3 months and 12 months after RTX infusion. Results: A total of 110 patients treated with biosimilar RTX were enrolled between May 2016 and July 2017. The mean age was 43.58 ± 11.77 years and the mean follow-up time was 16.22 ± 3.45 months. A notable decrease in PDAI score, anti-Dsg 1,3 level and prednisolone dosage was observed. Median delay to achieve complete remission (CR), median duration of CR, and median time to relapse were 3, 9, and 12 months, respectively. Newly diagnosed patients (NDPs) experienced higher rate of CR, longer duration of remission and lower risk of relapse, compared to previously treated patients (PTPs). A total of 47 AEs were observed in 33 (30%) patients, which were mostly mild infusion-related reactions. Conclusion: Administration of biosimilar RTX in PV patients was associated with desirable outcomes in terms of efficacy and safety in both NDPs and PTPs.First-line use of RTX in NDPs was more effective and allowed a rapid tapering of corticosteroid doses compared to PTPs. © 2019 Taylor & Francis Group, LLC.
Related Docs
View other Related Docs
1. Rituximab in Practice: Clinical Evaluation of Patients With Pemphigus After Rituximab Administration, Dermatologic Therapy (2021)
2. Sixteen-Year History of Rituximab Therapy for 1085 Pemphigus Vulgaris Patients: A Systematic Review, International Immunopharmacology (2018)
3. Updated S2k Guidelines on the Management of Pemphigus Vulgaris and Foliaceus Initiated by the European Academy of Dermatology and Venereology (Eadv), Journal of the European Academy of Dermatology and Venereology (2020)
4. Iranian Guideline for Rituximab Therapy in Pemphigus Patients, Dermatologic Therapy (2019)
5. Rituximab Therapy Improves Recalcitrant Pemphigus Vulgaris, EXCLI Journal (2015)
6. Comparing the Short-Term Therapeutic Effects and Safety Profiles of Rituximab Therapy in Pemphigus Vulgaris Patients Either Early Treated or Later Than Six Months, Journal of Dermatological Treatment (2019)
7. Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab, International Journal of Women's Dermatology (2019)
8. Comparing Early and Late Treatments With Rituximab in Pemphigus Vulgaris: Which One Is Better?, Archives of Dermatological Research (2019)
Experts (# of related papers)
View all Related Experts
Maryam Daneshpajooh (40)
Kamran Balighi (30)
Other Related Docs
9. Rituximab in Childhood and Juvenile Autoimmune Bullous Diseases As First-Line and Second-Line Treatment: A Case Series of 13 Patients, Journal of Dermatological Treatment (2020)
10. Rituximab Exhibits a Better Safety Profile When Used As a First Line of Treatment for Pemphigus Vulgaris: A Retrospective Study, International Immunopharmacology (2021)
11. Unexpected Worsening of Pemphigus Vulgaris After Rituximab: A Report of Three Cases, International Immunopharmacology (2019)
12. Intralesional Injection of Biosimilar Rituximab in Recalcitrant Mucocutaneous Lesions of Patients With Pemphigus Vulgaris: A Pilot Study, Dermatologic Therapy (2020)
13. Evaluating the Risk-To-Benefit Ratio of Using Cotrimoxazole As a Pneumocystis Pneumonia Preventative Intervention Among Pemphigus Patients Treated With Rituximab: A Retrospective Study With 494 Patients, Dermatologic Therapy (2022)
14. Comparison of Topical Nanocolloidal Silver Formulation Use With Eosin 2% Solution in Management of Hard-To-Heal Ulcers in Patients With Pemphigus Vulgaris, Journal of Wound Care (2020)
15. Single-Nucleotide Polymorphisms Associated With Pemphigus Vulgaris: Potent Markers for Better Treatment and Personalized Medicine, International Journal of Immunogenetics (2020)
16. Investigating Expression Pattern of Eight Immune-Related Genes in Pemphigus Patients Compared With the Healthy Controls and After Rituximab Therapy: Potential Roles of Ctla4 and Fcgr3a Genes Expression in Outcomes of Rituximab Therapy, Dermatologic Therapy (2020)
17. A Systematic Review on Efficacy, Safety, and Treatment-Durability of Low-Dose Rituximab for the Treatment of Pemphigus: Special Focus on Covid-19 Pandemic Concerns, Immunopharmacology and Immunotoxicology (2021)
18. Applicability of Glucocorticoid Toxicity Index in Pemphigus: Comparison Between Two Groups of Rituximab-Treated and Rituximab-Naive Patients, Dermatologic Therapy (2022)
19. Elevated Serum Level of B-Cell Activating Factor (Baff) After Rituximab Therapy in Pemphigus Vulgaris Patients Suggests a Possible Therapeutic Efficacy of B-Cell Depletion Therapies Combined With Anti-Baff Agents, International Journal of Dermatology (2023)
20. Prevalence of Fungal Infections in Pemphigus Patients: A Systematic Review and Meta-Analysis, Mycoses (2024)
21. Paradoxical Reaction to Rituximab in Patients With Pemphigus: A Report of 10 Cases, Immunopharmacology and Immunotoxicology (2020)
22. Pathogenic and Protective Roles of Cytokines in Pemphigus: A Systematic Review, Cytokine (2020)
23. “Change Over Time in the Treatment of Pemphigus Vulgaris Between 2004 and 2016 in Iran”: A Multiple Cross-Sectional Study, Dermatologic Therapy (2019)
24. Anti-Desmoglein-1 Levels As Predictor of Prednisolone Tapering in Pemphigus Vulgaris Patients Treated With Rituximab, Dermatologic Therapy (2018)
25. Multiple Cycles of Rituximab Therapy for Pemphigus: A Group of Patients With Difficult- To-Treat Disease or a Consequence of Late Rituximab Initiation?, Dermatologic Therapy (2022)
26. Rituximab Treatment and Improvement of Health-Related Quality of Life in Patients With Pemphigus, Cutis (2023)
27. Burden of Pemphigus Vulgaris With a Particular Focus on Women: A Review, International Journal of Women's Dermatology (2022)
28. Pulmonary Nocardiosis in Pemphigus Vulgaris Patients From Tehran, Iran, Infectious Disorders - Drug Targets (2021)
29. Pemphigus Disease and Area Index: Unmet Needs in the Real-World Management of Pemphigus, Oral Diseases (2023)
30. Odss Vs. Absis and Pdai Oral Parts in Pemphigus Vulgaris: Inter-Rater Reliability and Testing Times, Oral Diseases (2023)
31. Covid-19 in Pemphigus Vulgaris Patients With Previous Rituximab Therapy: A Tele-Medicine Experience, Journal of Dermatological Treatment (2020)
32. Covid-19: The Experience From Iran, Clinics in Dermatology (2021)
33. Pharmacogenetics: A Strategy for Personalized Medicine for Autoimmune Diseases, Clinical Genetics (2018)
34. Immunologic Prediction of Relapse in Patients With Pemphigus Vulgaris (Pv) in Clinical Remission, Journal of the American Academy of Dermatology (2016)
35. Anagen Hair Loss, Anti-Desmoglein 1, and Pemphigus Disease Area Index: A Signifi Cant Relationship?; [Anagener Haarverlust, Anti-Desmoglein 1 Und Pemphigus Disease Area Index: Ein Signifi Kanter Zusammenhang?], JDDG - Journal of the German Society of Dermatology (2017)
36. Drug-Induced Pemphigus: A Systematic Review of 170 Patients, International Immunopharmacology (2021)
37. High Dietary Acid Load Predicts Severity of Autoimmune Skin Disease: A Cross-Sectional Study, Scientific Reports (2024)
38. Relationship of Blood Groups to Pemphigus: Do Blood Group Antigens Have a Biological Role? a Case-Control Study, Iranian Journal of Dermatology (2017)
39. Pemphigus Trigger Factors: Special Focus on Pemphigus Vulgaris and Pemphigus Foliaceus, Archives of Dermatological Research (2018)
40. Towards Personalized Medicine for Patients With Autoimmune Diseases: Opportunities and Challenges, Immunology Letters (2017)
41. Decreased Serum Levels of Interleukin-4 and Interleukin-21 in New Pemphigus Vulgaris Patients, But Not Chronic Patients With Inactive Disease Compared to Healthy Controls, Dermatology Practical and Conceptual (2021)
42. The Effect of L-Carnitine Supplementation on Serum Levels of Omentin-1, Visfatin and Sfrp5 and Glycemic Indices in Patients With Pemphigus Vulgaris: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Phytotherapy Research (2020)
43. Self-Assessment Pemphigus Vulgaris Activity Score (Sa-Pvas): A New Tool for Patients to Self-Assess Their Disease Severity, Australasian Journal of Dermatology (2022)
44. Tofacitinib As the Potent Treatment for Refractory Pemphigus: A Possible Alternative Treatment for Pemphigus, Dermatologic Therapy (2018)
45. Autoimmune Blistering Diseases Treated With Glucocorticoids: An International Study of Steroid-Induced Myopathy, Journal of the European Academy of Dermatology and Venereology (2025)
46. International Bullous Diseases Group: Consensus on Diagnostic Criteria for Epidermolysis Bullosa Acquisita, British Journal of Dermatology (2018)
47. Estimated Cut-Off Values for Pemphigus Severity Classification According to Pemphigus Disease Area Index (Pdai), Autoimmune Bullous Skin Disorder Intensity Score (Absis), and Anti-Desmoglein 1 Autoantibodies, BMC Dermatology (2020)
48. Exacerbation of Autoimmune Bullous Diseases After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination: Is There Any Association?, Frontiers in Medicine (2022)
49. Retrospective Study of Gingival Involvement in Pemphigus: A Difficult to Treat Phenomenon, Dermatologic Therapy (2022)